Cargando…
Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials
OBJECTIVE: To describe clinical features and disease progression of Selenoprotein N‐related myopathy in a large multicenter cohort of patients. METHODS: Cross‐sectional multicenter data analysis of 60 patients (53 families) with Selenoprotein N‐related myopathy and single‐center retrospective longit...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664282/ https://www.ncbi.nlm.nih.gov/pubmed/33037864 http://dx.doi.org/10.1002/acn3.51218 |
_version_ | 1783609814179381248 |
---|---|
author | Silwal, Arpana Sarkozy, Anna Scoto, Mariacristina Ridout, Deborah Schmidt, Anne Laverty, Aidan Henriques, Matilde D'Argenzio, Luigi Main, Marion Mein, Rachael Manzur, Adnan Y Abel, Francois Al‐Ghamdi, Fouad Genetti, Casie A Ardicli, Didem Haliloglu, Goknur Topaloglu, Haluk Beggs, Alan H Muntoni, Francesco |
author_facet | Silwal, Arpana Sarkozy, Anna Scoto, Mariacristina Ridout, Deborah Schmidt, Anne Laverty, Aidan Henriques, Matilde D'Argenzio, Luigi Main, Marion Mein, Rachael Manzur, Adnan Y Abel, Francois Al‐Ghamdi, Fouad Genetti, Casie A Ardicli, Didem Haliloglu, Goknur Topaloglu, Haluk Beggs, Alan H Muntoni, Francesco |
author_sort | Silwal, Arpana |
collection | PubMed |
description | OBJECTIVE: To describe clinical features and disease progression of Selenoprotein N‐related myopathy in a large multicenter cohort of patients. METHODS: Cross‐sectional multicenter data analysis of 60 patients (53 families) with Selenoprotein N‐related myopathy and single‐center retrospective longitudinal analysis of 25 patients (21 families) over a median period of 5.3 years. RESULTS: The majority of patients (46/60, 77%) presented before age 2 years with hypotonia, poor head/neck control, and developmental delay. At last assessment (median age 14 years; range 2.5 to 36 years), 10/60 patients had minimal or no ambulation. Ventilatory support was initiated in 50/60 patients at a mean Forced Vital Capacity (FVC) of 38% and at a median age of 13 years. Forty‐five/60 patients developed scoliosis (at median age 12.1 years) and 18 had scoliosis surgery at a median age of 13.6 years. Five children needed nasogastric feeds and/or gastrostomy. Longitudinal data analysis on 25 patients showed progressive decline of Hammersmith functional motor scores (estimated annual change −0.55 point), time to walk 10 meter, time standing from sitting, and from lying. Sixteen patients had weights < 2nd centile. The estimated change in FVC % per year was −2.04, with a 95% CI (−2.94, −1.14). CONCLUSIONS: This comprehensive analysis of patients with Selenoprotein N‐related myopathy further describes the clinical course of this rare condition. The observed functional motor and respiratory data provide evidence of the slow decline patients experience over time which is useful when considering therapeutic intervention. |
format | Online Article Text |
id | pubmed-7664282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76642822020-11-17 Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials Silwal, Arpana Sarkozy, Anna Scoto, Mariacristina Ridout, Deborah Schmidt, Anne Laverty, Aidan Henriques, Matilde D'Argenzio, Luigi Main, Marion Mein, Rachael Manzur, Adnan Y Abel, Francois Al‐Ghamdi, Fouad Genetti, Casie A Ardicli, Didem Haliloglu, Goknur Topaloglu, Haluk Beggs, Alan H Muntoni, Francesco Ann Clin Transl Neurol Research Articles OBJECTIVE: To describe clinical features and disease progression of Selenoprotein N‐related myopathy in a large multicenter cohort of patients. METHODS: Cross‐sectional multicenter data analysis of 60 patients (53 families) with Selenoprotein N‐related myopathy and single‐center retrospective longitudinal analysis of 25 patients (21 families) over a median period of 5.3 years. RESULTS: The majority of patients (46/60, 77%) presented before age 2 years with hypotonia, poor head/neck control, and developmental delay. At last assessment (median age 14 years; range 2.5 to 36 years), 10/60 patients had minimal or no ambulation. Ventilatory support was initiated in 50/60 patients at a mean Forced Vital Capacity (FVC) of 38% and at a median age of 13 years. Forty‐five/60 patients developed scoliosis (at median age 12.1 years) and 18 had scoliosis surgery at a median age of 13.6 years. Five children needed nasogastric feeds and/or gastrostomy. Longitudinal data analysis on 25 patients showed progressive decline of Hammersmith functional motor scores (estimated annual change −0.55 point), time to walk 10 meter, time standing from sitting, and from lying. Sixteen patients had weights < 2nd centile. The estimated change in FVC % per year was −2.04, with a 95% CI (−2.94, −1.14). CONCLUSIONS: This comprehensive analysis of patients with Selenoprotein N‐related myopathy further describes the clinical course of this rare condition. The observed functional motor and respiratory data provide evidence of the slow decline patients experience over time which is useful when considering therapeutic intervention. John Wiley and Sons Inc. 2020-10-10 /pmc/articles/PMC7664282/ /pubmed/33037864 http://dx.doi.org/10.1002/acn3.51218 Text en © 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Silwal, Arpana Sarkozy, Anna Scoto, Mariacristina Ridout, Deborah Schmidt, Anne Laverty, Aidan Henriques, Matilde D'Argenzio, Luigi Main, Marion Mein, Rachael Manzur, Adnan Y Abel, Francois Al‐Ghamdi, Fouad Genetti, Casie A Ardicli, Didem Haliloglu, Goknur Topaloglu, Haluk Beggs, Alan H Muntoni, Francesco Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials |
title | Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials |
title_full | Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials |
title_fullStr | Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials |
title_full_unstemmed | Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials |
title_short | Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials |
title_sort | selenoprotein n‐related myopathy: a retrospective natural history study to guide clinical trials |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664282/ https://www.ncbi.nlm.nih.gov/pubmed/33037864 http://dx.doi.org/10.1002/acn3.51218 |
work_keys_str_mv | AT silwalarpana selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT sarkozyanna selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT scotomariacristina selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT ridoutdeborah selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT schmidtanne selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT lavertyaidan selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT henriquesmatilde selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT dargenzioluigi selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT mainmarion selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT meinrachael selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT manzuradnany selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT abelfrancois selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT alghamdifouad selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT genetticasiea selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT ardiclididem selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT haliloglugoknur selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT topalogluhaluk selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT beggsalanh selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials AT muntonifrancesco selenoproteinnrelatedmyopathyaretrospectivenaturalhistorystudytoguideclinicaltrials |